Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic condition do not produce sufficient clotting factors, which can cause ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...

Researchers have created liver tissue that grows its own blood vessels, improving research into hemophilia and liver damage.

Certain immune markers in the blood may help predict ITI response among hemophilia A patients given immune tolerance ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Hemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. 4 It is estimated to affect approximately 1,125,000 people ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Hemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. 4 It is estimated to affect approximately 1,125,000 people ...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and ...